Dear Editor
We thank you for the opportunity to respond to the comments made by Ware et al. (2014) on our recently published article "The Need for Human Breast Cancer Resistance Protein Substrate and Inhibition Evaluation in Drug Discovery and Development: Why, When, and How?" (Poirier et al., 2014) . The relevance of breast cancer resistance protein (BCRP) in drug discovery and development is clearly an important topic and we are pleased to see that our article raises further interest and discussion.
In our article, we primarily focused on a number of key aspects around the in vitro assessment of BCRP interactions (substrate and inhibition), supported by our own data. In the Discussion, we then aimed to put the in vitro results into context with in vivo data for BCRPmediated interactions. For the latter purpose, an extensive survey of the literature was conducted and the relevant information currently available for BCRP-mediated interactions was summarized in our Table 1 (Poirier et al, 2014) . It should be noted that in addition to sulfasalazine, we reviewed 13 other BCRP substrates to put the in vitro BCRP results into context and to see an overall picture of its clinical relevance-the main focus of our article. Furthermore, we wanted to highlight that BCRPmediated drug-drug interactions (DDIs), as for other transporters, can rarely be tracked to a single mechanism; they are often confounded by multiple interactions with other transporters and/or drug-metabolizing enzymes. This is a common paradigm in the scientific/drug metabolism and pharmacokinetics community.
We acknowledge the specific points raised by Ware et al. (2014) concerning BCRP-sulfasalazine interaction studies and regret if our article might furnish the impression that sulfasalazine may not be a suitable substrate for in vivo DDI studies for BCRP inhibition. This was not our intention, nor did we make such concrete statements in our article. Furthermore, we had cited all of the relevant references concerned with sulfasalazine, including the references cited by Ware et al. (2014) . In our Table 1 (Poirier et al., 2014) , we indicated that the range for the sulfasalazine area under the curve changes from ,2-to 4-fold for pharmacogenetic studies and up to 3.2-fold for DDI studies. We discussed the diverging (animal to human) and partly controversial data of sulfasalazine interactions with cautiousness and without making firm recommendations, stating that "It might therefore be a possibility that the mechanism of the sulfasalazine/curcumin interaction is not only an inhibition of BCRP but also an inhibition of the bacterial degradation of sulfasalazine in the intestine." This sentence was only partly cited by Ware et al. (2014) ; by omitting the first part of the sentence, a wrong impression might be given.
On the basis of the current scientific knowledge, final answers and recommendations about the conduct and extrapolation of BCRP inhibition data are difficult to give. This was likewise not the intention of our article, in which we discussed BCRP-mediated transport assessment in drug development through new in vitro results as well as relevant published clinical studies. In agreement with Ware et al. (2014) , we recommend integrated, case-by-case approaches for BCRP evaluation, using all preclinical and clinical tools available.
